Effects of luteinizing hormone-releasing hormone analogue on DNA synthesis in rat prostate and uterus.
Buserelin, a potent LH-RH agonist, has been used for the treatment of hormonal disorders such as precocious puberty, endometriosis, cystic mastitis and prostatic carcinoma. Prolonged treatment with buserelin has been known to induce a refractory phase of pituitary desensitization. In the present study, we found that two-week treatment with buserelin strongly suppressed the activities of thymidylate synthetase and thymidine kinase, and markedly reduced the appearance of BrdU-immunoreactive (S-phase) cells in both prostate glands and uteri in male and female adult rats, respectively.
Medical Research Institute, Tokyo Medical and Dental University, Japan.
S
S
Sakamoto
M
M
Tajima
K
K
Sawaki
S
S
Suzuki
H
H
Kudo
S
S
Sassa
K
K
Kuwa
Y
Y
Sugiura
N
N
Kasahara
H
H
Nagasawa
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002064:Buserelin / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis*; D004971:Estrus / Q000502:physiology; D005260:Female; D007150:Immunohistochemistry; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013739:Testosterone / Q000097:blood; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism
D013739:Testosterone; D004247:DNA; D002064:Buserelin